![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
100% SVR12 WITH ABT-493 AND ABT-530 WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAÏVE HCV GENOTYPE 3-INFECTED PATIENTS WITH CIRRHOSIS
|
|
|
Reported by Jules Levin
51st Annual Meeting of the European Association for the Study of the Liver
• Barcelona, Spain • 16 April 2016
Paul Y Kwo1, David L Wyles2, Stanley Wang3, Fred Poordad4, Edward Gane5, Benedict Maliakkal6, Mitchell L Shiffman7, Teresa I Ng3, Chih-Wei Lin3, Ran Liu3, Jens Kort3, Federico J Mensa3
1Indiana University School of Medicine, Indianapolis, Indiana, USA; 2University of California San Diego, La Jolla, California, USA; 3AbbVie Inc., North Chicago, IL, USA; 4Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 5University of Auckland, Auckland, New Zealand; 6University of Rochester Medical Center, Rochester, New York, USA; 7Liver Institute of Virginia, Bon Secours Health System, Newport News and Richmond, VA, USA
![EASL1](../images/041916/041916-3/EASL1.gif)
![EASL2](../images/041916/041916-3/EASL2.gif)
![EASL3](../images/041916/041916-3/EASL3.gif)
![EASL4](../images/041916/041916-3/EASL4.gif)
![EASL5](../images/041916/041916-3/EASL5.gif)
![EASL6](../images/041916/041916-3/EASL6.gif)
![EASL7](../images/041916/041916-3/EASL7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|